Table 2 Characteristics and outcomes of patients
ID | Age | Gender | Disease | CART inj | CART | CRS | ICANS | Day 30 PET-scan | Follow-up | Outcome (Feb 19, 2021) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Grade | Post infusion | Grade | Post infusion | |||||||||
UPN #1 | 65 | F | NHL GCB 3rd line | January 27, 2020 | axi-cel | 2 | D2 | NA | NA | CR | CR (M12) | Alive |
UPN #2 | 67 | M | NHL GCB 3rd line | February 7, 2020 | 0 | NA | NA | NA | CR | Relapse (M12) | Alive | |
UPN #3 | 66 | M | NHL GCB 3rd line | February 21, 2020 | 2 | D2 | 4 | D5 | CR | Relapse (M18) | Alive | |
UPN #4 | 72 | F | NHL GCB 3rd line | May 12, 2020 | 2 | D12 | 2 | D17 | CR | CR (M110) | Alive | |
UPN #5 | 67 | M | NHL GCB 3rd line | May 25, 2020 | 2 | D5 | 2 | D11 | CR | Relapse (M14) | Dead (Oct 3, 2020) | |
UPN #6 | 65 | M | NHL GCB 4th line | June 2, 2020 | 2 | D1 | 3 | D6 | CR | CR (M8) | Alive | |
UPN #7 | 52 | M | NHL GCB 4th line | June 12, 2020 | 2 | D2 | 1–2 | D14 | PR | CR (M8) | Alive | |
UPN #8 | 70 | F | NHL GCB 3rd line | July 20, 2020 | 1 | D2 | 3 | D5 | Progression | Refractory | Dead (Oct 8, 2020) | |
UPN #9 | 54 | F | DLBCL (tFL), 3rd line | May 13, 2019 | 0 | NA | 0 | NA | CR | CR (M12) | Alive (Jun 4, 2020) | |
UPN #10 | 69 | F | DLBCL NGC, 5th line | July 11, 2019 | 2 | D5 | 2 | D6 | CR | CR (M12) | Alive (Jul 9, 2020) | |
UPN #11 | 25 | M | B-ALL, 3rd line | April 3, 2019 | tisa-cel | 0 | NA | 0 | NA | CR, negative MRD | persisting B cell aplasia (M23), CD19low relapse (M23) | Alive (Mar 5, 2021) |
UPN #12 | 55 | M | DLBCL GC, 3rd line | July 9, 2019 | 2 | D3 | 0 | NA | PR | CR (M18) | Alive Jan 11, 2021 | |
UPN #13 | 62 | M | DLBCL (tFL), 6th line | June 4, 2019 | 0 | NA | 0 | NA | CR | CR (M18) | Alive (Mar 1, 2021) | |
UPN #14 | 23 | M | Phi + B-ALL, previous allograft, 2nd line | June 12, 2019 | 1 | D8 | 0 | NA | CR, negative MRD | Loss of B cell aplasia (M6), molecular relapse (M6), CR with negative MRD (M19) after TKI treatment | Alive (Jan 21, 2021) | |
UPN #15 | 56 | M | DLBCL (tFL), 4th line | September 24, 2019 | 2 | D4 | 1 | D7 | CR | CR (M17) | Alive (Feb 18, 2021) | |
UPN #16 | 15 | M | B-ALL, previous allograft, 4th line | January 28, 2020 | 0 | NA | 0 | NA | CR, negative MRD | CD19 + relapse (M6) | Alive (Feb 18, 2021) | |
UPN #17 | 19 | F | B-ALL, 3rd line | June 16, 2020 | 0 | NA | 0 | NA | CR, negative MRD | CR with negative MRD (M1), Loss of B cell aplasia (M2), CR (M2), follow up in another center | Alive (Aug 17, 2020) | |